Direct-to-consumer Drug Ads may Be a Waste of Cash

by Rajashri on September 3, 2008 at 11:23 AM
 Direct-to-consumer Drug Ads may Be a Waste of Cash

A new report says that Big Pharma may be throwing away billions of dollars on ad campaigns in the United States in an effort to promote a drug directly with the public.

In 1997, the United States lifted a ban on prescription-drug ads that are pitched directly at the public rather than at doctors or other health professionals.


The change prompted pharmaceutical companies to invest heavily in retail advertising, and annual spending in this sector now averages more than five billion dollars (four billion euros).

Advocates of direct-to-public drug advertising say it raises awareness and encourages the treatment of neglected conditions.

Critics counter that it artificially drives up demand for expensive novel drugs that have not been tested over the long haul.

Both sides, though, have assumed that the marketing technique works -- but the new study suggests they have got it flat wrong.

"People tend to think that if direct-to-consumer advertising wasn't effective, Pharma wouldn't be doing it," said Harvard Medical School professor Stephen Soumerai, who led the investigation.

"But as it turns out, decisions to market directly to consumers are based on scant data."

Even when sales increase, it has been nearly impossible to isolate the impact of targeting consumers from, say, marketing campaigns directed at doctors and health professionals.

Ideally, one would want to compare two otherwise identical populations before and after one of them is exposed to direct-to-consumer ads for certain drugs in order to measure the difference.

In the United States that is not possible, so Soumerai came up with a clever idea: Canada.

Direct-to-consumer ads for prescription drugs are illegal north of the US border, but English-speaking Canadians are still massively exposed to pharma advertising on American television and radio, and in US magazines.

Their French-speaking neighbours in the Canadian province of Quebec, however, are not, which provided the investigators with a useful group for making a comparison.

The study focused on three drugs: Enbrel, for arthritis; Nasonex, for allergies; and Zelnorm, for irritable bowel syndrome.

All three had been on the market in both countries for at least one year before the direct-to-consumer campaigns began in the United States.

The question was simple: once the ads kicked in, did sales increase more quickly in English-speaking Canada than in Quebec?

Based on data from a registry of 2,700 pharmacies, the answer for the first two drugs was a clear "no", while for the third drug, sales initially leapt in the Canadian anglophone market but then fell back.

The study was published online on Tuesday by the British Medical Journal (BMJ).

Sales of Zelnorm initially jumped 40 percent, but within a couple of years prescription rates in both groups were the same again.

Given that Zelnorm was the only drug available for that syndrome, it might have sold as well without the direct-to-consumer ads.

Soumerai thinks the ads failed because the process of buying prescription drugs is not as easy or spontaneous as buying over-the-counter medication such as aspirin.

A person has to see an ad, get motivated, contact their doctor, show up for an appointment, communicate both the condition and the drug, convince the doctor to prescribe it, and then actually fill the prescription, which is also likely to carry an out-of-pocket cost, he explained.

The United States is one of only two countries in the world -- along with New Zealand -- where direct-to-consumer ads for prescription medication is legal.

In March 2007, Zelnorm was pulled from the market due to concerns about increased risk of heart attack and stroke.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Direct-to-consumer Drug Ads may Be a Waste of Cash Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests